Convexal subarachnoid haemorrhage in a patient under pembrolizumab-lenvatinib combination therapy

被引:0
|
作者
Simao, Paulo [1 ,2 ]
Almeida, Marco Jose [3 ]
Catela, Joao [4 ]
Matias, Fernando [3 ]
机构
[1] Ctr Hosp & Univ Coimbra EPE, Internal Med, Campus Hosp Univ Coimbra, Coimbra, Portugal
[2] Ctr Hosp & Univ Cova Beira EPE, Internal Med, Covilha, Portugal
[3] Ctr Hosp & Univ Coimbra EPE, Neurol, Campus Hosp & Univ Coimbra, Coimbra, Portugal
[4] Ctr Hosp & Univ Coimbra EPE, Neurosurg, Coimbra, Portugal
关键词
Epilepsy and seizures; Neuroimaging; Non-vascular; Gynecological cancer; Unwanted effects / adverse reactions; CELL LUNG-CANCER; MELANOMA;
D O I
10.1136/bcr-2023-256100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A woman in her 60s was brought to the emergency department due to a new-onset seizure. She was drowsy on arrival and unable to provide a clinical history. She had a medical history of advanced endometrial cancer, for which she was under the therapeutic protocol pembrolizumab plus lenvatinib. Laboratorial investigations were unremarkable. The brain CT angiography provided further insight into the case by detecting a bilateral convexal subarachnoid haemorrhage with discrete bilateral opercular vasogenic oedema, without other noticeable structural changes. Cerebrospinal fluid analysis was macroscopically haemorrhagic, but otherwise unremarkable. The brain MRI did not provide additional information. Although considered a rare adverse reaction, cerebral haemorrhage has been described for both pembrolizumab and lenvatinib. We cautiously assumed a probable drug aetiology after a thorough review of potential causes. Following discontinuation of these drugs and under anti-convulsive therapy, the patient remained asymptomatic and was discharged home.
引用
收藏
页数:3
相关论文
共 50 条
  • [41] A case report of robot-assisted radical nephrectomy and inferior vena cava thrombectomy in a patient with renal cell carcinoma after pembrolizumab and axitinib combination therapy
    Shiode, Ryo
    Noda, Terutaka
    Nobumori, Shota
    Sugihara, Naoya
    Yamakawa, Maki
    Saiki, Kaori
    Sawada, Takatora
    Kono, Reina
    Kakuda, Toshio
    Nishimura, Kenichi
    Fukumoto, Tetsuya
    Miura, Noriyoshi
    Miyauchi, Yuki
    Kikugawa, Tadahiko
    Saika, Takashi
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (09) : 5141 - 5148
  • [42] Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.
    Rimassa, Lorenza
    Li, Daneng
    Ikeda, Masafumi
    Yarchoan, Mark
    Ryoo, Baek-Yeol
    Kossler, Thibaud
    Lim, Ho-Yeong
    Kwiatkowski, Mariusz
    Chang, Ting-Tsung
    Kim, Jee Hyun
    Casadei-Gardini, Andrea
    Kudo, Masatoshi
    Ren, Zhenggang
    Calvo, Maria Varela
    Llovet, Josep M.
    Zhang, Yayan
    Hatogai, Ken
    Siegel, Abby B.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 484 - 484
  • [43] The Association of Urological Oncology First-line Therapy for Patients with advanced clear cell Renal Cell Carcinoma An open, randomized Phase-III Trial for Evaluating the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902) or MK-1308A in Combination with Lenvatinib versus Pembrolizumab and Lenvatinib as First-line Treatment in Patients with advanced Clear Cell Renal Cell Carcinoma (ccRCC) (AN 54/21 of the Association of Urological Oncology, HIF-012)
    Rexer, H.
    Bedke, J.
    Busch, J.
    UROLOGE, 2021, 60 (12): : 1636 - 1638
  • [44] Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775.
    Makker, Vicky
    Colombo, Nicoletta
    Santin, Alessandro
    Miller, David Scott
    Fujiwara, Keiichi
    Pignata, Sandro
    Ray-Coquard, Isabelle Laure
    Kim, Yong Man
    Guerra, Eva M.
    Huang, Jie
    Barresi, Gianmaria
    McKenzie, Jodi
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Successful Combination Therapy of BRAF- and MEK-Inhibitor after Progress under BRAF-Inhibitor Mono Therapy: Report of a Patient with brain metastatic Melanoma
    Asper, H.
    Satger, I
    Tolk, H.
    Kapp, A.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 166 - 166
  • [46] Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
    Shimizu, Akihiro
    Shirai, Izumi
    Ogawa, Kyohei
    Miura, Akane
    Haruhara, Kotaro
    Oshiro, Kentaro
    Hamaguchi, Akihiko
    Yokote, Shinya
    Okabe, Masahiro
    Ueda, Hiroyuki
    Tsuboi, Nobuo
    Ikeda, Masato
    Yokoo, Takashi
    INTERNAL MEDICINE, 2022, 61 (24) : 3703 - 3708
  • [47] KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab plus lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
    Kramer, Gero
    Shore, Neal D.
    Joshua, Anthony M.
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [48] Phase Ib/II trial of pembrolizumab (pembro) plus lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F
    Kramer, G.
    Shore, N. D.
    Joshua, A. M.
    Li, X. T.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J. S.
    Yu, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S669 - S670
  • [49] A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib plus pembrolizumab or avelumab in first line therapy (PREPARE; AIO-NZK-0115/ass).
    Gruenwald, Viktor
    Jacobasch, Lutz
    de Wit, Maike
    Banek, Severine
    Niegisch, Guenter
    Zahn, Mark-Oliver
    Neisius, Andreas
    Marks, Phillip
    Mueller, Mirko
    von Weikersthal, Ludwig
    Huebner, Andreas
    Augustin, Marinela
    von der Heyde, Eyck
    Thomas, Christian
    Gilbert, Nils
    Fehr, Alexander
    Stauder, Heribert
    Vehling-Kaiser, Ursula
    Eckert, Ralf
    Ivanyi, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 523 - 523
  • [50] First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma A randomized, double-blind Phase-3-Study Comparing the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) versus Pembrolizumab and Placebo as First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma who are not suitable for a Cisplatin-based Therapy and whose Tumors express PD-L1, as well as for Patients who are not suitable for a platinum-based Therapy regardless of the PD-L1-Expression (LEAP-011-AB 68/18 of the AUO)
    Rexer, H.
    Retz, M.
    Kramer, M.
    AKTUELLE UROLOGIE, 2021, 52 (01) : 28 - 29